Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Effects on fertility

Description of key information

OECD 422: NOAEL 3000mg/kg bw/d (test material, a.i. 951mg/kg) (reproductive, developmental and systemic toxicty)

Link to relevant study records
Reference
Endpoint:
screening for reproductive / developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Study period:
Feb 2017 - Mar 2018
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
Deviations:
no
GLP compliance:
yes (incl. QA statement)
Specific details on test material used for the study:
A.I. 31.7%
test material contains 68.3% water
Species:
rat
Strain:
Wistar
Details on species / strain selection:
strain Crl:WI(Han), supplied by Charles River Laboratories, Research Models and Services, Germany GmbH/ Charles River Laboratories, France, which were free from any clinical signs of disease
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH/ Charles River Laboratories, France
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation (when arrived from breeder): males (11 weeks old) and females (10 weeks old)
- Weight at study initiation: see raw data
- Fasting period before study:
- Housing: During the pretreatment period, the rats were housed together (up to 5 animals per sex and cage) in Polysulfonate cages Typ 2000P (H-Temp) supplied by TECHNIPLAST, Hohenpeißenberg, Germany.
During the study period, the rats were housed individually in Polycarbonate cages type III supplied by TECHNIPLAST, Hohenpeißenberg, Germany and Becker & Co., Castrop-Rauxel, Germany, with the following exceptions: During overnight matings, male and female mating partners were housed together in Polycarbonate cages type III and Pregnant animals and their litters were housed together until PND 13 in Polycarbonate cages type III.
- Diet (e.g. ad libitum): ground Kliba maintenance diet mouse/rat “GLP” meal, supplied by Provimi Kliba SA, Kaiseraugst, Switzerland, which was available to the animals ad libitum throughout the study
- Water (e.g. ad libitum): Drinking water was supplied from water bottles (ad libitum).
- Acclimation period: 3 weeks

DETAILS OF FOOD AND WATER QUALITY: see above

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24C
- Humidity (%): 30-70%
- Air changes (per hr): 15 times per hour
- Photoperiod (hrs dark / hrs light): 12 hours light from 6.00 h to 18.00 h and 12 hours darkness

Route of administration:
oral: gavage
Vehicle:
water
Details on exposure:
PREPARATION OF DOSING SOLUTIONS:
The test substance solutions in drinking water were prepared in intervals, which took into account the analytical results of the stability verification. For the preparation of the administration solutions the test substance was weighed in a
graduated flask depending on the dose group, topped up with drinking water and intensely mixed with a magnetic stirrer.

VEHICLE
- Justification for use and choice of vehicle (if other than water): water
Details on mating procedure:
In general, each of the male and female animals was mated overnight in a 1:1 ratio for a maximum of 2 weeks. Throughout the mating period, each female animal was paired with a
predetermined male animal from the same dose group.
The animals were paired by placing the female in the cage of the male mating partner from about 16.00 h until 6.30 - 9.00 h of the following morning. Deviations from the specified times
were possible on weekends and public holidays and were reported in the raw data. A vaginal smear was prepared after each mating and examined for the presence of sperm. If sperm was
detected, pairing of the animals was discontinued. The day on which sperm were detected was denoted " gestation day (GD) 0" and the following day "gestation day (GD) 1"
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
The analytical investigations of the test substance preparations were carried out as a separate study at the test facility Competence Center Analytics of BASF SE, 67056 Ludwigshafen, Germany. (internal study nr.)

Analytical verifications of the stability of the test substance in drinking water for a period of 7 days at room temperature were carried out before the study was initiated and confirmed.

At the beginning (during premating), twice during gestation and once during lactation of the study each 1 sample was taken from the low, mid and high concentration for a concentration
control analysis. All test samples, plus a duplicate set of reserve samples, were withdrawn by staff of the Reproduction Toxicology.
The samples collected at the beginning of the administration period and during lactation were analyzed in the Analytical Laboratory. The samples of the gestation were analyzed only if any imprecision occurs during the analysis
of the samples from the beginning and lactation of the study. The samples within this study were labeled with serial numbers. The same number was not used for several samplings.
Duration of treatment / exposure:
The duration of treatment covered a 2-week pre-mating and a mating period, approximately 1 day post-mating in males, and the entire gestation period as well as approximately 21 days of the lactation period and 29 days post-mating in females (for
sperm negative female).
Frequency of treatment:
daily
Details on study schedule:
The male and female rats were 10 - 11 weeks old when they arrived from the breeder. During an acclimatization period of about 3 weeks, estrous cycle determination prior to treatment were performed in a pool of up to 50 non-randomized female animals. Animals with no regular estrous cycle and/or animals with the lowest and highest body weights were eliminated from the study and used for other purposes. The 40 male and 40 female animals included in the study were 13 - 14 weeks old at the beginning of treatment and the weight variation of the animals used did not exceed 20 percent of the mean weight of each sex.
The assignment of the animals to the different test groups was carried out using a randomization program, according to their weight one day before the beginning of the administration period (day -1).
After the acclimatization period, the test substance was administered to the parental animals orally by gavage, once daily at approximately the same time in the morning.Females in labor
were not treated. The treatment lasted up to one day prior to sacrifice. The animals of the control group were treated with the vehicle (drinking water), in the same way.
A detailed clinical observation (DCO) was performed in all animals once before the start of the administration period and thereafter at weekly intervals.
Males and females from the same dose group were mated, after two weeks of treatment, overnight at a ratio of 1:1.
The females were allowed to deliver and rear their pups until PND 4 (standardization) or PND 13.
Dose / conc.:
300 mg/kg bw/day (actual dose received)
Remarks:
test material contains 68.3% water
Dose / conc.:
1 000 mg/kg bw/day (actual dose received)
Remarks:
test material contains 68.3% water
Dose / conc.:
3 000 mg/kg bw/day (actual dose received)
Remarks:
test material contains 68.3% water
Dose / conc.:
95.1 other: mg/kg bw/d a.i.
Remarks:
corrected to a.i. (31.7% of actual dose)
Dose / conc.:
317 other: mg/kg bw/d a.i.
Remarks:
corrected to a.i. (31.7% of actual dose)
Dose / conc.:
951 other: mg/kg bw/d a.i.
Remarks:
corrected to a.i. (31.7% of actual dose)
No. of animals per sex per dose:
10
Control animals:
yes, concurrent vehicle
Details on study design:
- Dose selection rationale: based on range finder study with 1000 and 3000 mg/kg bw actual received.
- Rationale for animal assignment (if not random): random
Positive control:
no
Parental animals: Observations and examinations:
CAGE SIDE OBSERVATIONS: Yes
A cageside examination was conducted at least daily for any signs of morbidity, pertinent behavioral changes and signs of overt toxicity before the administration as well as within 2 hours and within 5 hours after the administration.

DETAILED CLINICAL OBSERVATIONS: Yes
A detailed clinical observation (DCO) was performed in all animals once before the start of the administration period and thereafter at weekly intervals.
Mortality: A check for moribund or dead animals was made twice daily on working days or once daily (Saturday, Sunday or on public holidays).
The parturition and lactation behavior of the dams was generally evaluated in the mornings in combination with the daily clinical inspection of the dams.
On weekdays (except Saturday, Sunday and public holidays) the parturition behavior of the dams was inspected in the afternoons in addition to the evaluations in the mornings.

DCO examinations are:
1. Abnormal behavior in “handling”
2. Fur
3. Skin
4. Posture
5. Salivation
6. Respiration
7. Activity/arousal level
8. Tremors
9. Convulsions
10. Abnormal movements
11. Gait abnormalities
12. Lacrimation
13. Palpebral closure
14. Exophthalmos (Protruding eyeball)
15. Assessment of the feces excreted during the examination (appearance/consistency)
16. Assessment of the urine excreted during the examination
17. Pupil size

BODY WEIGHT: Yes
In general, the body weight of the male and female parental animals was determined once a week at the same time of the day (in the morning) until sacrifice.
Females without positive evidence of sperm, without litter or waiting for necropsy, were weighed weekly.

FOOD CONSUMPTION:
Generally, food consumption was determined once a week for male and female parentalanimals, with the following exceptions: Food consumption was not determined after the 2nd premating week (male parental
animals) and during the mating period (male and female F0 animals). Food consumption of the F0 females with evidence of sperm was determined on gestation days (GD) 0 - 7, 7 - 14 and 14 - 20. Food consumption of F0 females which gave birth to a litter was determined on PND 1 - 4, 4 - 7, 7 - 10 and 10 - 13.
Food consumption was not determined in females without positive evidence of sperm during the mating and the gestation period and in females without litter during the lactation period.

WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
Water consumption of the females with evidence of sperm was determined for GD 7-8, 14-15 and 19-20.
Water consumption of the F0 females, which gave birth to a litter was determined for PND 1-2, 3-4, 6-7, 9-10 and 12-13.
Water consumption was not determined in the females without positive evidence of sperm during mating and gestation periods and in the females without litter during lactation period.

HAEMATOLOGY: Yes
In the morning blood was taken from the retro-bulbar venous plexus from fasted animals. The animals were anaesthetized using isoflurane. The blood sampling procedure and subsequent
analysis of blood and serum samples were carried out in a randomized sequence. The parameters listed below were examined in the first 5 surviving parental males per group
at termination and in the first 5 females with litters (in order of delivery) per group at PND 14.
Parameters checked:
Leukocyte count (WBC)
Erythrocyte count (RBC)
Hemoglobin (HGB)
Hematocrit (HCT)
Mean corpuscular volume (MCV)
Mean corpuscular hemoglobin (MCH)
Mean corpuscular hemoglobin concentration (MCHC)
Platelet count (PLT)
Differential blood count
Reticulocytes (RETA)
Prothrombin time (Hepato Quick’s test) (HQT)


CLINICAL CHEMISTRY: Yes
see Haematology for details of blood sampling.
Parameters measured are:
Enzyme:
Alanine aminotransferase (ALT) (L-alanine: 2-oxoglutarate aminotransferase)
Aspartate aminotransferase (AST) (L-aspartate: 2-oxoglutarate aminotransferase)
Alkaline phosphatase (ALP) (orthophosphoric acid monoester phosphohydrolase)
g-Glutamyltransferase (GGT) (g -glutamyl) peptide: aminoacid-g-glutamyl-transferase)
Blood Chemistry Parameters:
Sodium (NA)
Potassium (K)
Chloride (CL)
Inorganic phosphate (INP)
Calcium (CA)
Urea (UREA)
Creatinine (CREA)
Glucose (GLUC)
Total bilirubin (TBIL)
Total protein (TPROT)
Albumin(ALB)
Globulins (GLOB)
Triglycerides (TRIG)
Cholesterol (CHOL)
Bile acids (TBA)

Thyroid Hormones
Blood samples were taken from all surplus pups or 2 preferably female pups per litter at PND 4 as well as one male and one female pup per litter at PND 13 by decapitation under isoflurane
anesthesia. Additionally, blood samples from all dams at PND 14 and all males at termination were taken by puncturing the retrobulbar venous plexus under isoflurane anesthesia. The adults were fastened before the blood sampling.
Parameters:
Total thyroxine (T4)
Thyroid stimulating hormone (TSH)

URINALYSIS: Not specified

NEUROBEHAVIOURAL EXAMINATION: Yes
A functional observational battery (FOB) was performed in the first 5 male and the first 5 female animals with litter per group (in order of delivery) at the end of the administration period starting at about 10.00 h.The FOB started in a randomized sequence with passive observations without disturbing the animals, followed by removal from the home cage, open field observations in a standard arena and sensorimotor tests as well as reflex tests.

Home cage observations:
The animals were observed in their closed home cages (for a short period: about 10-30 seconds); any disturbing activities (touching the cage or rack, noise) were avoided during these examinations in order not to influence the behavior of the animals.Attention was paid to:
1. Posture
2. Tremors
3. Convulsions
4. Abnormal movements
5. Gait
6. Other findings

Open field observations:
The animals were transferred to a standard arena (50 × 50 × 25 cm) and observed.The following parameters were examined:
1. Behavior on removal from cage
2. Fur
3. Skin
4. Salivation
5. Nasal discharge
6. Lacrimation
7. Eyes/pupil size
8. Posture
9. Palpebral closure
10. Respiration
11. Tremors
12. Convulsions
13. Abnormal movements/stereotypy
14. Gait
15. Activity/arousal level
16. Feces (appearance/ consistency) within 2 minutes
17. Urine (amount/color) within 2 minutes
18. Rearing within 2 minutes
19. Other findings

Sensory motor tests/Reflexes:
The animals were removed from the open field and subjected to following sensory motor or reflex tests:
1. Reaction to an object being moved towards the face (Approach response)
2. Touch sensitivity (Touch response)
3. Vision (Visual placing response)
4. Pupillary reflex
5. Pinna reflex
6. Audition (Startle response)
7. Coordination of movements (Righting response)
8. Behavior during handling
9. Vocalization
10. Pain perception (Tail pinch)
11. Other findings
12. Grip strength of forelimbs
13. Grip strength of hindlimbs
14. Landing foot-splay test

Motor activity measurement
The Measurement of motor activity (MA) was measured at the end of the administration period in the first 5 surviving parental males and the first 5 surviving females with litter (in order of delivery) per group.

Male reproduction data
The pairing partners, the number of mating days until vaginal sperm was detected in the female animals, and the gestational status of the females were recorded for F0 breeding pairs. For the males, mating and fertility indices were calculated

Female reproduction and delivery data
The pairing partners, the number of mating days until vaginal sperm was detected and gestational status was recorded for F0 females. For the females, mating, fertility and gestation indices were calculated.

Oestrous cyclicity (parental animals):
For all females in a pool of up to 50 animals, estrous cycle normality was evaluated before the randomization (the estrous cycle data of these individuals were not be reported and can be found in the raw data).
For a minimum of 2 weeks prior to mating estrous cycle length was evaluated by daily analysis of vaginal smear for all F0 female parental rats. Determination was continued throughout the pairing period until the female exhibited evidence of copulation. At necropsy, an additional vaginal smear was examined to determine the stage of estrous cycle for each F0 female with scheduled sacrifice.
Sperm parameters (parental animals):
Special attention was given to the stages of spermatogenesis and histopathology of interstitial testicular cell structure.
Litter observations:
Pup number and status at delivery:
All pups delivered from the F0 parents (F1 litter) were examined as soon as possible on the day of birth to determine the total number of pups, the sex and the number of liveborn and stillborn pups in each litter.
Pup viability/mortality:
In general, a check was made for any dead or moribund pups twice daily on workdays (once in the morning and once in the afternoon) or as a rule, only in the morning on Saturdays, Sundays or public holidays.
Sex ratio:
On the day of birth (PND 0) the sex of the pups was determined by observing the distance between the anus and the base of the genital tubercle; normally, the anogenital distance is considerably greater in male than in female pups. Later, during the course of lactation, this initial sex determination was followed up by surveying the external appearance of the anogenital region and the mammary line. The sex of the pups was finally confirmed at necropsy.
Pup clinical observations
The live pups were examined daily for clinical symptoms (including gross-morphological findings) during the clinical inspection of the dams and documented for each pup.
Pup body weight data
The pups were weighed on the day after birth (PND 1) and on PND 4 (before standardization), 7, 10 and 13. Pups' body weight change was calculated from these results.
Postmortem examinations (parental animals):
All parental animals were sacrificed by decapitation under isoflurane anesthesia. The exsanguinated animals were necropsied and assessed by gross pathology, special attention being given to the reproductive organs.

GROSS PATHOLOGY: Yes (see table)

Organ weights

The following weights were determined in all animals sacrificed on schedule:
1. Anesthetized animals
2. Epididymides
3. Ovaries
4. Prostate
5. Seminal vesicles with coagulating glands
6. Testes
7. Thyroid glands (fixed)
8. Uterus (with cervix)

The following weights were determined in 5 animals per sex/test group:
1. Adrenal glands
2. Brain
3. Heart
4. Kidneys
5. Liver
6. Spleen
7. Thymus

Organ/tissue fixation
The following organs or tissues of all parental animals were fixed:
1. All gross lesions
2. Adrenal glands
3. Aorta
4. Bone marrow (femur)
5. Brain
6. Cecum
7. Cervix
8. Coagulating glands
9. Colon
10. Duodenum
11. Eyes with optic nerve (males in 4% buffered formaldehyde solution; females in modified
Davidson’s solution)
12. Esophagus
13. Extraorbital lacrimal glands
14. Epididymides (modified Davidson’s solution)
15. Femur with knee joint
16. Heart
17. Ileum
18. Jejunum (with Peyer’s patches)
19. Kidneys
20. Larynx
21. Liver
22. Lungs
23. Lymph nodes (axillary and mesenteric)
24. Mammary gland (male and female)
25. Nose (nasal cavity)
26. Ovaries (modified Davidson’s solution)
27. Oviducts
28. Pancreas
29. Parathyroid glands
30. Pharynx
31. Pituitary gland
32. Prostate gland
33. Rectum
34. Salivary glands (mandibular and sublingual)
35. Sciatic nerve
36. Seminal vesicles
37. Skeletal muscle
38. Spinal cord (cervical, thoracic and lumbar cord)
39. Spleen
40. Sternum with marrow
41. Stomach (forestomach and glandular stomach)
42. Testes (modified Davidson’s solution)
43. Thymus
44. Thyroid glands
45. Trachea
46. Urinary bladder
47. Uterus (uteri of all apparently nonpregnant animals or empty uterus horns were stained
according to Salewski E,1964)
48. Vagina

HISTOPATHOLOGY: Yes (see table)
Fixation was followed by histotechnical processing, examination by light microscopy and assessment of findings according to the following table was performed for the highest dose group and the control at minimum:
1. All gross lesions
2. Adrenal glands
3. Brain
4. Cecum
5. Cervix
6. Coagulating glands
7. Colon
8. Duodenum
9. Epididymides
10. Eyes with optic nerve
11. Heart
12. Ileum
13. Jejunum
14. Kidneys
15. Liver
16. Lungs
17. Lymph nodes (axillary and mesenteric)
18. Ovaries
19. Oviducts
20. Prostate gland
21. Peyer’s patches
22. Rectum
23. Sciatic nerve
24. Seminal vesicles
25. Skeletal muscle
26. Spinal cord (cervical, thoracic, lumbar)
27. Spleen
28. Sternum with marrow
29. Stomach (forestomach and glandular stomach)
30. Testes
31. Thymus
32. Thyroid glands
33. Trachea
34. Urinary bladder
35. Uterus
36. Vagina
Postmortem examinations (offspring):
On PND 4, as a result of standardization, the surplus pups or 2 preferably female pups per litter, respectively, were sacrificed under isoflurane anesthesia by decapitation. Blood was
sampled for determination of thyroid hormone concentrations (see 3.9.). After sacrifice, the pups were examined externally and eviscerated, and the organs were assessed
macroscopically.
On PND 13, one selected male and one female pup per litter was sacrificed under isoflurane anesthesia by decapitation. Blood was sampled for determination of thyroid hormone
concentrations. Thyroid glands/parathyroid glands were fixed in neutral buffered 4% formaldehyde solution and were transferred to the Pathology Laboratory for possible further processing.
The remaining pups were sacrificed under isoflurane by decapitation. After sacrifice, all pups were examined externally and eviscerated, and their organs were assessed macroscopically.
All stillborn pups and all pups that died before weaning were examined externally, eviscerated and their organs were assessed macroscopically. All pups without notable findings or abnormalities were discarded after their macroscopic evaluation. Animals with notable findings or abnormalities were evaluated on a case-by-case basis, depending on the type of finding noted.
Statistics:
The following statistical analyses were carried out:see any other
Reproductive indices:
Male mating index
Male fertility index
Female mating index
Female fertility index
Gestation index
Postimplantation loss
Offspring viability indices:
Live birth index
Viability index
Survival index
Sex ratio
anogenital index
Clinical signs:
effects observed, non-treatment-related
Description (incidence and severity):
Five high-dose males (Nos.: 31, 35, 37, 38 and 39 - 3000 mg/kg bw/d) showed salivation (slight to moderate) during mating days 11 – 14. One high-dose male (No.: 39) showed salivation
(slight) on post-mating day 0. Four high-dose females (Nos.: 134, 137, 138 and 140) showed salivation (slight to moderate) during several parts of the gestation period.
One high-dose female (No. 137) showed a skin lesion (head region) during GD 14 - 22 and PND 1 - 5 and skin lesion (entire body) during PND 6 - 19.
One control male (No. 2) showed gasping and labored respiration on premating day 9. One high-dose female (No.: 140) had a complete litter loss on PND 8.
These isolated findings were considered as incidental, as they occurred without any relation to the test substance administration.
Mortality:
no mortality observed
Body weight and weight changes:
no effects observed
Food consumption and compound intake (if feeding study):
no effects observed
Description (incidence and severity):
The statistically significantly decreased food consumption of the high-dose F0 females during PND 1 - 4 was assessed as incidental as it was mainly caused by one animal (No. 140) which
delivered only two pups and subsequently no increasing food consumption during lactation was seen.
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
no effects observed
Ophthalmological findings:
not specified
Haematological findings:
effects observed, non-treatment-related
Description (incidence and severity):
In males of test group 3 (3000 mg/kg bw/d), absolute and relative monocyte counts were significantly lower compared to controls. This was also true for absolute monocyte counts in
males of test group 1 (300 mg/kg bw/d). However, the means were within historical control ranges (males, absolute monocytes 0.07-0.14 Giga/L; relative monocytes 1.3-2.7 %), whereas
at least absolute monocyte counts of the controls were above the historical control range. Therefore, these changes were regarded as incidental and not treatment-related.
In females of test group 3 (3000 mg/kg bw/d) hemoglobin values were significantly lower compared to controls, but the values were within the historical control range (females,
hemoglobin 8.4-9.2 mmol/L). Therefore, this alteration was regarded as incidental and not treatment-related.
Clinical biochemistry findings:
no effects observed
Description (incidence and severity):
Clinical chemistry: No treatment-related changes among clinical chemistry parameters were observed.
Thyroid hormones: In parental males (300, 1000 and 3000 mg/kg bw/d) and in male and female pups at PND13
(300, 1000 and 3000 mg/kg bw/d), no treatment-related alterations of T4 and TSH levels were
observed.
Urinalysis findings:
not examined
Behaviour (functional findings):
no effects observed
Description (incidence and severity):
The statistically significantly increased value in the high-dose males during interval 1 was assessed as incidental as the summation of all intervals was not statistically significantly
increased and no similar effect was seen in female animals which were treated for a considerably longer period.
Immunological findings:
not specified
Organ weight findings including organ / body weight ratios:
effects observed, non-treatment-related
Histopathological findings: non-neoplastic:
no effects observed
Description (incidence and severity):
All findings occurred either individually or were biologically equally distributed over control and treatment groups. They were considered to be incidental or spontaneous in origin and without
any relation to treatment. The stages of spermatogenesis in the testes of males of the high dose test group were comparable to those of the controls. In high dose females the different stages of functional
bodies in the ovaries were present and comparable to the control animals.
Fertility
The female animals (Nos. 105 and 111), which were not pregnant showed increased mucification of the vagina and cervix with atrophy of the epithelium beneath. This finding represents a spontaneous background lesion which might influence fertility. In animal No. 111, following findings were also noted: inflammation of the urinary bladder and urethra (both accompanied by epithelial hyperplasia), dilation of the ureters and plasmocytosis in the iliac lymph nodes. These findings were consistent with the macroscopic changes. (see above)
Reproductive function: oestrous cycle:
no effects observed
Description (incidence and severity):
Estrous cycle data, generated during the last 2 weeks prior to mating for the F1 litter, revealed regular cycles in the females of all test groups 0 - 3. The mean estrous cycle duration was
similar: 4 days in test groups 0 - 3, respectively.
Reproductive function: sperm measures:
no effects observed
Description (incidence and severity):
The stages of spermatogenesis in the testes of males of the high dose test group were comparable to those of the controls. In high dose females the different stages of functional
bodies in the ovaries were present and comparable to the control animals.
Reproductive performance:
no effects observed
Description (incidence and severity):
Pup number and status at delivery
The mean number of delivered F1 pups per dam and the rates of liveborn, stillborn, found dead and cannibalized F1 pups were evenly distributed among the test groups. The respective values reflect the normal range of biological variation inherent in the strain used in this study.
Pup viability
The viability index indicating pup mortality during lactation (PND 0 - 4) varied between 100%/
99.3% /95.6% and 92.9% in test groups 0 - 3, respectively.
The pups surviving index indicating pup mortality during lactation (PND 4 - 13) varied between 100%/ 100% /100% and 87.5% in test groups 0 - 3, respectively. The supposedly decreased values in the high dose group are attributable to one female (No.: 140) which had only two pups (one found dead at day 1 and one cannibalized at day 8). These isolated finding was assessed as incidental and not related to the treatment.
Sex ratio
The sex distribution and sex ratios of live F1 pups on the day of birth and PND 4 did not show substantial differences between the control and the test substance-treated groups; slight
differences were regarded to be spontaneous in nature.
Pup clinical observations
There were no test substance-related adverse clinical signs observed in any of the F1 generation pups of the different test groups.
Pup body weight data
No test substance-related influence on body weights and body weight change values of F1 pups were noted in test groups 1 - 3 (300, 1000 and 3000 mg/kg bw/d). One male runt was seen in test group 2.
Anogenital distance/anogenital index
Neither on anogenital distance nor anogenital index test substance-related effects were noted in all treated F1 offspring (test groups 1 - 3 [300, 1000 and 3000 mg/kg bw/d]).
Nipple/ areola anlagen
The apparent number and percentage of male pups having areolae was not influenced by the test substance when examined on PND 13.
Pup necropsy observations
A few pups showed spontaneous findings at gross necropsy, such as discolored testis (left, brown), small testis, empty stomach and partly cannibalized.
These findings occurred without any relation to dosing and/or can be found in the historical control data at comparable or even higher incidences
Key result
Dose descriptor:
NOAEL
Effect level:
3 000 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
other: no adverse effects up to and including the highest tested dosage
Key result
Dose descriptor:
NOAEL
Effect level:
>= 951 mg/kg bw/day
Based on:
act. ingr.
Sex:
male/female
Basis for effect level:
other: no adverse effects up to and including the highest tested dosage
Clinical signs:
no effects observed
Mortality / viability:
mortality observed, non-treatment-related
Body weight and weight changes:
no effects observed
Food consumption and compound intake (if feeding study):
not specified
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
no effects observed
Clinical biochemistry findings:
no effects observed
Urinalysis findings:
not examined
Sexual maturation:
no effects observed
Description (incidence and severity):
The sex distribution and sex ratios of live F1 pups on the day of birth and PND 4 did not show substantial differences between the control and the test substance-treated groups; slight differences were regarded to be spontaneous in nature.
Neither on anogenital distance nor anogenital index test substance-related effects were noted in all treated F1 offspring (test groups 1 - 3 [300, 1000 and 3000 mg/kg bw/d]).
The apparent number and percentage of male pups having areolae was not influenced by the test substance when examined on PND 13.
Organ weight findings including organ / body weight ratios:
no effects observed
Gross pathological findings:
effects observed, non-treatment-related
Description (incidence and severity):
A few pups showed spontaneous findings at gross necropsy, such as discolored testis (left, brown), small testis, empty stomach and partly cannibalized.
These findings occurred without any relation to dosing and/or can be found in the historical control data at comparable or even higher incidences
Histopathological findings:
no effects observed
Key result
Dose descriptor:
NOAEL
Generation:
F1
Effect level:
>= 3 000 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
other: no adverse effects up to and including the highest tested dosage
Key result
Dose descriptor:
NOAEL
Generation:
F1
Effect level:
>= 951 mg/kg bw/day
Based on:
act. ingr.
Sex:
male/female
Basis for effect level:
other: no adverse effects up to and including the highest tested dosage
Key result
Reproductive effects observed:
no
Conclusions:
In conclusion, under the conditions of the present OECD 422 combined repeated dose toxicity study with the reproductive/developmental screening test in Wistar rats the oral administration
of [trade name] by gavage to male and female Wistar rats did not result in signs of systemic toxicity up to a dose level of 3000 mg/kg bw/d (951 mg/kg bw/d a.i. due to 68.3% water content) . Thus, the no observed adverse effect level
(NOAEL) for general systemic toxicity was 3000 mg/kg bw/d (951 mg/kg bw/d a.i.) for male and female Wistar rats. The NOAEL for reproductive performance and fertility was also set to 3000 mg/kg bw/d (951 mg/kg bw/d a.i.) for
male and female Wistar rats. The NOAEL for developmental toxicity was 3000 mg/kg bw/d (951 mg/kg bw/d a.i.).
Effect on fertility: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
951 mg/kg bw/day
Study duration:
subacute
Species:
rat
Quality of whole database:
KL 1
Additional information

In an OECD 422 study, the test compound Reaction product of propargylchloride and sodium bisulfitewas administered daily to groups of 10 male and 10 female Wistar rats (F0 animals) by gavage at doses of 300, 1000 and 3000 mg/kg body weight/day (mg/kg bw/d) to screen for potential systemic, reproductive and developmental toxicity (BASF SE 2018, 85R0178/16R070). The doses were adjusted due to the water content of 68.3% of the test substance. Control animals (10 male and 10 female Wistar rats) were dosed daily with the vehicle only (drinking water). After a two-week premating period, these parental animals were mated and the females were allowed to give birth and bring up the offspring until sacrifice on PND 4 or PND 13.

Regarding clinical examinations, signs of general systemic toxicity were not observed in male or female parental animals of test groups 1-3 during the entire study period. Temporarily several male and female animals of test group 3 (3000 mg/kg bw/d) showed salivation after treatment. From the temporary, short appearance immediately after dosing it is likely, that this finding was induced by a bad taste of the test substance or local affection of the upper digestive tract. This finding was not considered to be an adverse and toxicologically relevant effect. Food consumption and body weight development in male and female animals was not altered by the test substance administration. In the subsequent investigations including the detailed clinical observation (DCO), the functional observational battery (FOB) and the measurement of motor activity (MA) no substance related differences to control were observed at any concentration. Fertility indices for male and female animals were not impaired by test-substance even at the limit dose of 3000 mg/kg bw/d. Mating behavior, conception, implantation and parturition were not influenced by the test substance administration. In addition, live birth indices of pups in all test groups were not influenced. The viability index as indicator for pup mortality was not impaired by the test-substance administration up to the highest dose tested (3000 mg/kg bw/d). Concerning clinical pathology no treatment-related, adverse effects were observed up to a dose of the compound of 3000 mg/kg bw/d. Regarding pathology, there were neither treatment-related organ weighs changes nor gross lesions. All histopathological findings occurred either individually or were biologically equally distributed over control and treatment groups. They were considered incidental or spontaneous in origin and without any relation to treatment.

In conclusion, under the conditions of the present OECD 422 combined repeated dose toxicity study with the reproductive/developmental screening test in Wistar rats the oral administration of Reaction product of propargylchloride and sodium bisulfite by gavage to male and female Wistar rats did not result in signs of systemic toxicity up to a dose level of 3000 mg/kg bw/d. Thus, the no observed adverse effect level (NOAEL) for general systemic toxicity was 3000 mg/kg bw/d for male and female Wistar rats. The NOAEL for reproductive performance and fertility was also set to 3000 mg/kg bw/d for male and female Wistar rats. The NOAEL for developmental toxicity was 3000 mg/kg bw/d.

Justification for classification or non-classification

Classification, Labelling, and Packaging Regulation (EC) No 1272/2008

The available experimental test data is reliable and suitable for classification purposes under Regulation (EC) No 1272/2008. As a result the substance is not considered to be classified for reproduction toxicity under Regulation (EC) No 1272/2008, as amended for the tenth time in Regulation (EU) No 2017/776.

Additional information